|Mr. Michael R. Minogue||1.58M||11.66M||50|
|Dr. David M. Weber Ph.D.||650.45k||9.91M||56|
|Mr. Michael G. Howley||574.37k||3.24M||53|
|Mr. William J. Bolt||567.42k||3.12M||65|
|Dr. Thorsten Siess||N/A||N/A||N/A|
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.
ABIOMED, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 7; Compensation: 5.